CTOs on the Move

AEG Vision

www.aegvision.com

 
AEG Vision supports and empowers eyecare professionals to grow their practices while elevating focus on delivering excellent eyecare.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.aegvision.com
  • 4835, Lyndon B Johnson Freeway
    Farmers Branch, TX USA 75244
  • Phone: 972.370.5552

Executives

Name Title Contact Details

Similar Companies

Pharvaris

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.

ReCept Pharmacy LP

ReCept Pharmacy LP is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

McKesson

McKesson Corporation, currently ranked 7th on the FORTUNE 500, we are a global healthcare services and medical supply company dedicated to delivering better care. We support the entire healthcare system, including pharmacies, hospitals, health systems, biotech and life sciences companies, specialty care and oncology practices, physician offices, surgery centers, and long-term care and home health facilities. We deliver pharmaceutical products, medical supplies and business services to each of these groups to create a world of better health.

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (“AUD using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.

Institute for OneWorld Health

Institute for OneWorld Health is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.